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0929-6646/Copyright ª 2015, FormosaBackground/Purpose: No formal epidemiological research based on systematic analysis has
focused on the relationship between herpes zoster and immunodeficiency virus (HIV) infection
in Taiwan. Our aim was to explore whether herpes zoster is an early manifestation of undiag-
nosed human HIV infection in Taiwan.
Methods: This was a retrospective cohort study using the database of the Taiwan National
Health Insurance Program. A total of 35,892 individuals aged  84 years with newly diagnosed
herpes zoster from 1998 to 2010 were assigned to the herpes zoster group, whereas 143,568 sex-
matched and age-matched, randomly selected individuals without herpes zoster served as the
non-herpes zoster group. The incidence of HIV diagnosis at the end of 2011 was estimated in
both groups. The multivariable Cox proportional hazards regression model was used to estimate
the hazard ratio and 95% confidence interval (CI) for risk of HIV diagnosis associated with herpes
zoster and other comorbidities including drug dependence and venereal diseases.
Results: The overall incidence of HIV diagnosis was 4.19-fold greater in the herpes zoster group
than that in the non-herpes zoster group (3.33 per 10,000 person-years vs. 0.80 per 10,000
person-years, 95% CI 4.04e4.35). The multivariable Cox proportional hazards regression anal-
ysis revealed that the adjusted hazard ratio of HIV diagnosis was 4.37 (95% CI 3.10e6.15) for in-
dividuals with herpes zoster and without comorbidities, as compared with individuals without
herpes zoster and without comorbidities.have no conflicts of interest relevant to this article.
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Herpes zoster and HIV 373Conclusion: Herpes zoster is associated with HIV diagnosis. Patients who have risk behaviors of
HIV infection should receive regular surveillance for undiagnosed HIV infection when they pre-
sent with herpes zoster.
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Herpes zoster, commonly known as shingles, is caused by
reactivation of latent varicella-zoster virus in the cranial-
nerve or dorsal-root ganglia.1,2 It is clinically characterized
by painful grouped vesicles on a erythematous rash along the
dermatome area, and it can result in chronic severe pain
(postherpetic neuralgia), particularly in older people.1e3 To
date, multiple risk factors of herpes zoster have been well
established, including immunosuppressive conditions, can-
cers, and chronic medical conditions.3e6 In addition, a
growing body of evidence reveals that the prevalence of
human immunodeficiency virus (HIV) infection is consider-
ably high among persons with high-risk behaviors presenting
with herpes zoster.7e9 Some studies have also revealed that
herpes zoster could be an early manifestation of undiag-
nosed HIV infection because of an early defect in cell-
mediated immunity.9e12 In Taiwan, the first HIV patient
was found in 1984, and at the end of 2013, the total number
of HIV patients had reached 26,475.13 To date, no formal
epidemiological research based on systematic analysis has
focused on the relationship between herpes zoster and HIV
infection in Taiwan. If herpes zoster is really an early
manifestation of undiagnosed HIV infection, patients with
high-risk behaviors of HIV infection should undergo testing
for undiagnosedHIV infectionwhen they presentwith herpes
zoster. Therefore, we conducted a population-based cohort
study using the database of the Taiwan National Health In-
surance Program to explore this issue.
Methods
Design and study population
This was a retrospective cohort study using the database of
the Taiwan National Health Insurance Program. The pro-
gram, which was implemented in March 1995, covers almost
99% of 23 million people living in Taiwan.14 The details of
the program have been well written in previous high-quality
studies.15e17 The study was approved by the Institutional
Review Board of China Medical University and Hospital in
Taichung, Taiwan (CMUH-104-REC2-115).
Study participants, comorbidities, and main
outcome measurement
We identified individuals aged  84 years with newly diag-
nosed herpes zoster as the herpes zoster group from 1998 to
2010, based on the International Classification of Diseases,
9th Revision (ICD-9 code 053). The date of diagnosing herpes
zoster was defined as the index date. Four folds ofcomparison individuals without herpes zosterwere randomly
selected from the same database to serve as the non-herpes
zoster group. The non-herpes zoster participants were
matched with the herpes zoster participants by sex, age
(every 5-year span), comorbidities, and the index year of
diagnosing herpes zoster. We excluded individuals with HIV
diagnosis (ICD-9 codes 795.71, V08, 042, and 079.53) at the
baseline in both groups. The following potential risk factors
for HIV infection were used: drug dependence (ICD-9 code
304) and venereal diseases (ICD-9 codes 090e099). All study
participants were followed until they were diagnosed with
HIV infection or until the end of 2011.
Statistical analysis
The distributions of sex, age, and comorbidities were
compared between the herpes zoster group and the non-
herpes zoster group using the Chi-square test for catego-
rized variables and t test for continuous variables. The
incidence of HIV diagnosis was estimated as the number of
HIV diagnosis event identified during the follow-up period,
divided by the total follow-up person-years for each group.
The multivariable Cox proportional hazards regression
model was used to estimate the hazard ratio and 95%
confidence interval (CI) for risk of HIV diagnosis associated
with herpes zoster and other comorbidities. The propor-
tional hazard model assumption was also examined using a
test of scaled Schoenfeld residuals. In the model evaluating
the risk of HIV diagnosis throughout overall follow-up
period, results of the test revealed a significant relation-
ship between Schoenfeld residuals for herpes zoster and
follow-up period, suggesting that the proportionality
assumption was violated (p Z 0.002). In the subsequent
analyses, we stratified the follow-up period to deal with the
violation of proportional hazard assumption. The statistical
significance level was set at two-sided p < 0.05. All ana-
lyses were performed using SAS software version 9.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Baseline characteristics of the study population
Table 1 shows the distributions of sex, age, and comorbid-
ities between the herpes zoster group and the non-herpes
zoster group. There were 35,892 individuals in the herpes
zoster group and 143,568 individuals in the non-herpes
zoster group, with similar distributions of sex and age.
The mean ages (standard deviation) of the study partici-
pants were 51.6  19.1 years for the herpes zoster group
and 51.2  19.2 years for the non-herpes zoster group. The
Table 1 Characteristics of the herpes zoster group and
the non-herpes zoster group.
Characteristic Non-herpes
zoster
N Z 143,568
Herpes zoster
N Z 35,892
pa
Sex 0.99
Male 68,424 (47.7) 17,106 (47.7)
Female 75,144 (52.3) 18,786 (52.3)
Age group (y) 0.99
<20 11,398 (7.9) 2848 (7.9)
20e39 26,321 (18.3) 6577 (18.3)
40e64 65,774 (45.8) 16,447 (45.8)
65e84 40,080 (27.9) 10,020 (27.9)
Age (y),
mean (SD) b
51.2 (19.2) 51.6 (19.1) <0.001
Baseline comorbidities
Drug
dependence
161 (0.11) 31 (0.09) 0.18
Venereal
diseases
222 (0.15) 66 (0.18) 0.22
SD Z standard deviation.
Data are presented as n (%) unless otherwise indicated.
a Chi-square test, comparing participants with and without
herpes zoster.
b t test, comparing participants with and without herpes
zoster.
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were equally distributed in both groups.Incidence of HIV diagnosis in the study population
The follow-up results revealed that the overall incidence of
HIV diagnosis was 4.19-fold greater in the herpes zosterTable 2 Incidence density of human immunodeficiency virus di
group.
Non-herpes zoster
N Event Person-years Ratea N
All 143,568 66 829,723 0.80 35
Sex
Male 68,424 56 390,349 1.43 17
Female 75,144 10 439,374 0.23 18
Age group (y)
<20 11,398 8 76,621 1.04 28
20e39 26,321 32 157,304 2.03 65
40e64 65,774 19 384,302 0.49 16
65e84 40,080 7 211,495 0.33 10
Follow-up period
3 mo 143,568 2 35,825 0.56 35
3e12 mo 142,990 5 106,325 0.47 35
1e3 y 139,734 23 244,931 0.94 34
>3 y 105,888 36 442,643 0.81 26
CI Z confidence interval; IRR Z incidence rate ratio.
a Incidence rate: per 10,000 person-years.
b IRR: herpes zoster versus non-herpes zoster (95% CI).group than that in the non-herpes zoster group (3.33 per
10,000 person-years vs. 0.80 per 10,000 person-years, 95%
CI 4.04e4.35). The incidence rates of HIV diagnosis, as
stratified by sex, age, and follow-up period, were all higher
in the herpes zoster group than those in the non-herpes
zoster group. Most new HIV diagnosis occurred in male in-
dividuals. The incidence rate of HIV diagnosis was higher in
male participants than in female participants in both
groups. The herpes zoster group aged 20e39 years had the
highest incidence rate of HIV diagnosis (8.56 per 10,000
person-years). The analysis stratified by follow-up period
revealed that the risk of HIV diagnosis persisted over time,
even after 1 year of diagnosing herpes zoster. However, the
risk appeared much higher during the 1-year follow-up
period, and was particularly highest in the first 3 months
with an incidence rate ratio of 14.0 (95% CI 13.3e14.8;
Table 2).
HIV diagnosis associated with herpes zoster and
other comorbidities
Drug dependence and venereal diseases were included as
comorbidities. The multivariable Cox proportional hazards
regression analysis revealed that the adjusted hazard ratio
of HIV diagnosis was 4.37 (95% CI 3.10e6.15) for individuals
with herpes zoster and without comorbidities, as compared
with individuals without herpes zoster and without comor-
bidities (Table 3).
The number needed to screen for HIV diagnosis
Table 4 shows that the number needed to screen for HIV
diagnosis was 520.2 (35,892/69) for the whole herpes zoster
group. In particular, the number needed to screen
decreased to 99 among male participants aged 21e30
years.agnosis in the herpes zoster group and the non-herpes zoster
Herpes zoster IRR (95% CI)b
Event Person-years Ratea
,892 69 206,906 3.33 4.19 (4.04e4.35)
,106 61 97,337 6.27 4.37 (4.15e4.60)
,786 8 109,569 0.73 3.21 (3.03e3.39)
48 2 19,130 1.05 1.00 (0.85e1.18)
77 34 39,708 8.56 4.21 (3.88e4.57)
,447 27 95,352 2.83 5.73 (5.41e6.06)
,020 6 52,716 1.14 3.44 (3.19e3.71)
,892 7 8951 7.82 14.0 (13.3e14.8)
,709 16 26,539 6.03 12.8 (12.2e13.4)
,862 28 61,051 4.59 4.88 (4.70e5.08)
,389 18 110,366 1.63 2.01 (1.91e2.10)
Table 3 Cox proportional hazards regression analysis for risk of human immunodeficiency virus diagnosis associated with
herpes zoster and comorbidities.
Variable Event Person-years Ratea Adjusted HRb (95% CI)
Herpes zoster Comorbiditiesc
No No 63 827,943 0.76 1 (Reference)
No Yes 3 1780 16.9 21.2 (6.65e67.7)
Yes No 68 206,375 3.29 4.37 (3.10e6.15)
Yes Yes 1 531 18.8 24.0 (3.34e172.9)
95% CI Z 95% confidence interval; HR Z hazard ratio.
a Incidence rate: per 10,000 person-years.
b Adjusted for sex and age.
c Comorbidities including drug dependence and venereal diseases.
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In this retrospective cohort study, we observed that the
overall incidence of HIV diagnosis was 4.19-fold greater in
the herpes zoster group than that in the non-herpes zoster
group. We also observed that patients with herpes zoster
were associated with 4.37-fold increased risk of HIV diag-
nosis. In this study, because we selected patients with
herpes zoster prior to the confirmed diagnosis of HIV, her-
pes zoster really preceded the serological detection of HIV.
Some studies have revealed that herpes zoster in areas with
high prevalence of HIV infection has an approximately 90%
positive predictive value for underlying HIV infec-
tion.11,18,19 Previous studies have established an increased
risk of herpes zoster among HIV-infected patients.20,21 This
risk can be reduced by highly active antiretroviral therapy,
but remains three times higher than that found in the HIV-
negative population.21,22 Therefore, our findings suggest
that herpes zoster could be an early manifestation of un-
diagnosed HIV infection in Taiwan, which is compatible with
the results of previous studies.9e12 We observed that most
new HIV diagnosis occurred in male participants (Table 2).
As shown in Table 4, among 61 male patients with HIV
diagnosis in the herpes zoster group, 47 male patients wereTable 4 Number needed to screen (NNS) for human immunode
Herpes zos
Female
N HIV diagnosis NNS
Overalla 18,786 8 2348.3
Age group (y)
1e10 (N Z 592) 300 0 d
11e20 (N Z 2256) 969 0 d
21e30 (N Z 3051) 1467 1 1467
31e40 (N Z 3526) 1736 1 1736
41e50 (N Z 5486) 3010 2 1505
51e60 (N Z 7793) 4542 2 2271
61e70 (N Z 6402) 3491 2 1745.5
71e80 (N Z 5402) 2631 0 d
>80 (N Z 1384) 640 0 d
a Overall NNS Z 520.2 (35,892/69).
b Fisher’s exact test, comparing male and female participants.aged 11e50 years (77%). We also observed that the risk of
HIV diagnosis appeared much higher during the 1-year
follow-up period, and is particularly high during the first 3
months (incidence rate ratio 14.0; Table 2). These findings
highlight that patients who have risk behaviors of HIV
infection should undergo tests for serological detection of
HIV when they present with herpes zoster, particularly for
younger male patients within 1 year of being diagnosed
with herpes zoster.
Several important limitations of this study should be
discussed. First, owing to the inherent limitation, some risk
behaviors of HIV infection, such as history of injection drug
use and history of sexual contact, were not recorded in this
database. Therefore, we used drug dependence as an
alternative variable instead of injection drug use and ve-
nereal diseases as an alternative variable instead of a his-
tory of sexual contact. Second, because of the same
limitation, whether patients had other symptoms or signs
potentially related to HIV infection other than herpes zos-
ter cannot be determined in this study. Third, we observed
that the risk of HIV diagnosis persisted over time, even up
to 3 years after the diagnosis of herpes zoster. Whether the
persistent risk is caused by risk behaviors introduced after
herpes zoster was diagnosed or by the latent status of HIVficiency virus diagnosis.
ter (N Z 35,892) pb
Male
N HIV diagnosis NNS
17,106 61 280.4 <0.001
292 0 d d
1287 2 643.5 0.22
1584 16 99 <0.001
1790 16 111.9 <0.001
2476 13 190.5 0.001
3251 7 464.4 0.03
2911 6 485.2 0.09
2771 1 2771 0.33
744 0 d d
376 S.-W. Lai et al.infection cannot be determined in this observational study.
Fourth, surveillance bias could be another possible expla-
nation for the association between herpes zoster and HIV
diagnosis. For example, patients with herpes zoster are
more likely to be screened and further to be identified for
their HIV diagnosis. Fifth, the number needed to screen for
HIV diagnosis was 520.2 in this study. The number needed to
screen decreased to 99 among male patients aged 21e30
years. In fact, not all herpes zoster patients need to be
screened for HIV diagnosis. Only those who have risk be-
haviors of HIV infection should receive screening for undi-
agnosed HIV infection when they present with herpes
zoster. Therefore, clinicians should collect complete his-
tories, such as history of injecting drug use and history of
sexual contact, to clarify whether patients with herpes
zoster are at an increased risk of HIV infection, particularly
among younger male patients. If clinicians can focus on
patients with risk behaviors, the number needed to screen
can be reduced.
In spite of the above-mentioned limitations, this study
was also noted to have several strengths. This is the first
population-based cohort study to explore the relationship
between herpes zoster and HIV diagnosis in Taiwan. This
study included a large sample size with long-term follow-up
period to increase its statistical power. It provides updated
information on herpes zoster and HIV diagnosis. We
conclude that herpes zoster is associated with HIV diag-
nosis. Herpes zoster could be an early and clinically
detectable manifestation of undiagnosed HIV infection in
Taiwan. Patients who have risk behaviors of HIV infection
should receive regular surveillance for undiagnosed HIV
infection when they present with herpes zoster, particu-
larly younger male patients within 1 year of being diag-
nosed with herpes zoster.Acknowledgments
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